At a glance
ClinicalIndex Comparison Record- ✓Age 18–88 years
- ✓BMI 20–40 kg/m²
- ✕Critically ill patients, patients on ventilators, or patients with hypotension whose safety may be compromised
- ✕Asthma or other condition where medical care/safety compromised by MRI
- ✕Claustrophobia
- ✕MRI contraindications: pacemaker, ICD, or metal implants
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Effects of Body Mass Index on the Hyperemic Response to Regadenoson
In Brief
A clinical study evaluating Adenosine and Regadenoson for Obesity and 2 related conditions. Completed, enrolled 30 participants across 1 site.
Detailed Summary
We will test the hypothesis that a single dose of Regadenoson will produce equivalent degrees of coronary hyperemia in patients of widely different body size. This will be a prospective, open-label, comparative trial using MRI to measure myocardial perfusion reserve (ratio of myocardial blood flow with vasodilator to myocardial blood flow at rest) during sequential administration of the coronary vasodilators adenosine and regadenoson. Non-invasive MRI measurements of resting myocardial blood flow, and sequential measurements of blood flow during adenosine infusion (weight adjusted dosing) and then blood flow during regadenoson infusion (single, fixed dose. Blood flow measurements will be obtained sequentially and in the same sequence in each subject during a two hour MRI exam. 32 subjects will be recruited for this study. The first 2 will be for testing of the protocol. Inclusion criteria: 2 subjects for initial protocol evaluation, then 30 subjects with body mass index (BMI) between 18 and 40. Exclusions are pregnancy, renal dysfunction and claustrophobia.
Study Details
Timeline
Interventions
Myocardial perfusion reserve measured with quantitative MRI during adenosine infusion (0.14 mg/kg/min x 6 minutes).
Myocardial perfusion reserve measured during regadenoson (0.4 mg/5 ml) bolus administration using quantitative perfusion MRI.